



RealRate

PHARMACEUTICAL 2021











PHARMACEUTICAL 2021



Merck & Co. Inc. Rank 98 of 402



The relative strengths and weaknesses of Merck & Co. Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Merck & Co. Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 84% points. The greatest weakness of Merck & Co. Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 41% points.

The company's Economic Capital Ratio, given in the ranking table, is 197%, being 150% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	27,764,000
Cost of Goods Sold	15,485,000
Intangible Assets	34,842,000
Liabilities, Current	27,327,000
Liabilities, Non-Current	0
Other Assets	10,996,000
Other Compr. Net Income	-456,000
Other Expenses	1,401,000
Other Liabilities	0
Other Net Income	0
Other Revenues	47,994,000
Property and Equipment	17,986,000
Research and Development	13,558,000
Selling, General and Administrative Expense	10,468,000

Output Variable	Value in 1000 USD
Assets	91,588,000
Liabilities	27,327,000
Expenses	40,912,000
Revenues	47,994,000
Stockholders Equity	64,261,000
Net Income	7,082,000
Comprehensive Net Income	6,854,000
Economic Capital Ratio	197%

